Market News

Closing of sale to Procter & Gamble at a cash purchase price of €3.4 billion completed.

Zenith Technology survey reveals that more than half of those surveyed believe that Industry 4.0 will drive the most change.

The gel formulation includes the progestin compound segesterone acetate, in combination with testosterone, and is applied to the back and shoulders and absorbed through the skin.

Company provided with exclusive rights to market a suite of Hansoh's injectable oncology medicines within the US for the next 5 years.

Expansion supports the growing needs of the company's pharmaceutical, biotechnology and CRO partners.

Cobra Biologics, Pall, and the Cell and Gene Therapy Catapult share £1.5 million grant from the UK's innovation agency.

Products containing Erdosteine from Recipharm are now marketed in over 40 countries across the world and is available in four different dosage forms.

Patients could receive faster treatment following boost to streamline the production of medicines and treatments.

Extra funding for strategic move into downstream formulation and fill finish capabilities and full exploitation of Lock-Release as new ADC manufacturing paradigm.

Company has successfully developed and validated impurity test methods in line with ICH Q3D regulatory guidelines.

Sartorius Stedim Biotech will continue to offer Lonza media and buffer products but under a non-exclusive agreement.

Wax-based and readily biodegradable: Euperlan OP White and Cegesoft Peel.

Event sees more innovation centralising at the Paris hub with entries for the awards and Start-up Hub opening.

Companies that have left it too late to implement their own solution will have to rely on support from providers, whose resources are already in high demand as the deadline approaches.

Trainees are provided with real-world examples of process workflows.

Larger headquarters will enable the company to free up space for additional laboratories and further expand capabilities.

Accreditation ensures quality and integrity of non-clinical laboratory studies to support pharmaceutical and biotech industries.

Company's manufacturing building for laboratory instruments in Göttingen wins the Global Excellence in Operations Award.

The absolute bioavailability of the Valtoco intranasal formulation was 96% of intravenous diazepam in a Phase I cross-over trial.

BioProduction’s content platform will be added to the bioLIVE exhibition, creating one of the world’s largest event hubs for the bio industry.

Despite Brexit looming, the company's EU & UK business has increased by almost 30% in the last 12 months.

Th company's CombiCult combinatorial cell culture technology will be used to generate high fidelity, progenitor and terminally differentiated neuronal and glial cell subtypes for incorporation into next-generation models.

Acquisition further strengthens Lonza’s commitment to drive the next generation of manufacturing patient-specific and personalized therapies.

With only a month to go, it really is too late to start trying to develop an in-house solution.

OPTi-OX technology allows the company to produce human cells of unprecedented quality, purity, and consistency.

Restriction due to potential cross-contamination.

Eight of the top ten pharma nations reporting improving market conditions.

CF3 coupled with UV-Vis detection able to separate and quantify the amount of free drug in a liposome-drug product.

‘One Site Shop’ expands to respond to growing demands.

BioVyon range have been incorporated into products to achieve more sensitive analysis, better healthcare, improved medical knowledge and faster diagnosis and treatment of diseases.

The new ‘Centre of Excellence’ already boasts one of the world’s most advanced gummy production line designed to meet demand from global markets.

The virtual platform is designed to allow the healthcare industry to effectively research and explore new technologies that will help to shape the future of the pharmaceutical supply chain.

Mylan achieves key milestone to provide US diabetes patients with more affordable generic version of Sanofi's Lantus insulin glargine vials.

New facility will offer customers the full range of services from development through to commercial-scale manufacturing

Accepting more complexity and risk is key for those generics companies seeking competitive differentiation by diversifying their product portfolios.

CMOs hit by reduced volumes of opioid manufacturing from DEA quota changes, but cannabis sales to ignite.

17 winners chosen from over 250 entries, with Nanobiotix winning both ‘CEO‘ and ‘Pharma Company of the Year’ categories.

Therapeutic ADC market expected to reach $4 billion by 2023.

The MG2 Tekna increases the CDMO’s manufacturing capacity to up to 500 million capsules per year.

Strengthens the CDMO's position as a centre of excellence as part of the viral vector drug development supply chain.

Partnership aims to increase the robustness and reduce costs for the manufacturing of AAV vectors.

Companies new to CPHI to showcase an exciting range of products and services ranging from electroceuticals to refrigerant alternatives.

Greater product protection thanks to reliable sealing technologies.

The PODs ease verification, qualification and validation challenges, and their flexibility allows them to support multiple products.

Idifarma's GMP spray drying technology for highly potent drugs up to Category 4 OEL/OEB is now operational.

Smaller bioreactors and high-density perfusion techniques needed as manufacturing makes significant efficiency improvements.

Facility to focus on developing and manufacturing the company's biosimilar portfolio.

Encorafenib in combination with binimetinib demonstrated 14.9 months median progression-free survival compared with vemurafenib monotherapy (7.3 months).

Lonza expansion includes drug substance development, and drug substance and drug product manufacturing.

GARDair removes the need for animal testing and opens a completely new market.

Provides single source of expertise for scaled production of complex biologics for gene therapy and vaccines.

The new Primary Care and China & Emerging Markets global business units are expected to launch at the beginning of 2019.

The Xelum R&D offers pharmaceutical manufacturers an ideal start to continuous OSD production.

Connection allows the marketing authorisation holders within the Recipharm Group to continue to supply medicines to patients post the EU FMD implementation date.

China is harmonizing to ICH standards at feverish pace and will force poor quality manufacturers out of market.

Pall and Aetos to advance the market impact of biosimilars and deliver lower-priced, high-quality options to end users.

Fruquintinib - innovative medicine that has not previously been launched in China or internationally - provides a new therapeutic approach for metastatic colorectal cancer patients.

The new services will focus on quality control analysis and stability testing of biopharmaceuticals.

The Sandoz US portfolios to be sold to Aurobindo include approximately 300 products, as well as additional development projects.

Novel, dual-acting product revitalizes and protects skin against blue light and environmental aggressors around the clock.

Faster GMP incident response and resolution times when manufacturing IT applications fail or are not running to their optimum capacity.

Customers to benefit from simplified, scalable solutions for intensified cell culture.

Company to use its combinatorial stem cell screening platform to develop technologies for the conversion of pluripotent stem cells into platelets.

US, Germany and Japan revealed as tier one nations in all categories with Sweden ranking the best of the rest.

Secure data sharing across the pharmaceutical industry.

New facility to carry out EU release testing ensuring continuous supply for customers regardless of the outcome of Brexit negotiations.

Life Science Factory gGmbH offers labs, co-working spaces and consulting services for life science entrepreneurs.

SGS's expansion will enable the service provider to offer a full ICH Q6B physico-chemical characterization of biological products.

CPHI Annual Report expert sees CDMOs as potentially a source of process innovation but warns both regulator and license holders need to move past regulatory diktats.

Investment will triple Sharp’s clinical service capacity for the pharmaceutical, biotech and clinical research sectors.

Leading antibiotics manufacturer reduces unacceptable levels of production downtime.

C-CIT Sensors launches its innovative and easy-to-handle single-use wireless bi-parametric metabolic monitoring system.

Investment will fuel the digitalization of the global pharmaceutical supply chain through the integration of real-time information-sharing, to create a highly predictable supply chain for the industry.

With only 6 months left in which to become EU FMD-compliant, how can companies make the best use of their now limited options?

The company’s engagement in Corporate Social Responsibility includes reducing consumption of water in manufacturing by using innovative technologies.

CPHI Middle East & Africa opens in Abu Dhabi as finished dosage formulations expand quickly, driven by government reforms to further increase local manufacturing.

Company's multimillion pound purpose-built facility becomes fully operational amidst growing interest worldwide in its potentially game-changing plant transient expression technology, Hypertrans.

Now less than a year away from when the UK officially leaves the EU, the main goal remains the same - maintaining access to new drugs for patient health.

Tadalafil is indicated in the treatment of pulmonary arterial hypertension to improve exercise ability.

New service to reliably and reproducibly isolate exosomes from almost any biofluid.

Company moves away from manual processing in favour of automated, scalable platforms.

Company recognised for its innovation and continual delivery of new natural ingredients.

EU approves Novartis's Aimovig, a first-of-its-kind treatment specifically designed for migraine prevention.

Agreement includes Pall's next-generation Kaneka KanCapA 3G sorbent for the primary capture of mAbs from clarified cell culture.

The first non-radioactive, dual-tracer for sentinel lymph node biopsy approved in the US.

The plant will be first-of-its-kind in the US.

Supporting EM programs in preparation for proposed EU GMP Annex 1 changes.

One company's positive approach to Brexit preparations, despite the lack of definition.

I Holland to share their 70 years' experience in an ‘ultimate’ tooling seminar.

The EMA needs to provide more action and guidance to help UK pharmaceutical manufacturers, says Thomas Beck, senior vice president, quality management, Recipharm.

Dedicated facility developed in response to increasing demand for product development projects in diagnostics, R&D and bioprocess.

Pall and BioSciencesCorp unite to provide "total solutions" for today's drug manufacturers.

First CDMO in China that is approved to supply commercial APIs for innovative drugs by regulatory agencies in the US, China, EU, Canada, Switzerland, Australia, and New Zealand.

WuXi STA chosen for its end-to-end CMC platform for new drug development.

To meet new PV regulations, the industry has to face a "multitude of unknowns and an ever-moving target".

The AGF 5000 is a machine with a compact and space-saving design, easy handling and a small number of format parts.

The ability to micro size drug-cell interactions will allow pharmaceutical and biotech companies to do 100x more testing for the same money spent as well as increasing productivity.

Parallel cell line development and analysis will allow for optimal cell line selection while compressing the development timeline.

Action ensures that the US is prepared should smallpox be used as a bioweapon.

FDF launches at CPHI Korea as country set to become regional hub.

Company will offer compliant products to all markets, including Europe and the US.

Dr Ramesh Jagadeesan, Sr. Director - Analytical Development at Recipharm, speaks to CPHI Online on the trends and challenges involved with conducting stability studies for firms that supply to multiple countries, and the advantages of using a contracto...

Winners will be announced live at the Gala Ceremony in Madrid with over 500 of Pharma’s top executives.

Company will be able to add 2D codes, human-readable text and tamper evidence to pre-packed medicines using existing equipment across its facilities.

Packaging technology is not a core Bosch business.

The latest developments in process development, nucleation control, scale-up of freeze drying cycles and development in lyophilization technology.

Consortium to develop advanced technologies for the manufacturing of ex vivo gene therapies.

Company's Wear Indicator Layer attracts the most attention.

Company consolidated as one of the leading laboratories in weight control thanks to the development of its existing range and new launches.

The topical treatment for hair loss boasts a 'commercial' formulation.

Experts warn bio industry needs to do more to create a sustainable pipeline of talent.

Ruling prevents Dr Reddy's Laboratories will from launching their alternative salt forms of pemetrexed until the patent expires.

Approval for seizures associated with Lennox-Gastaut Syndrome or Dravet Syndrome, two rare, severe childhood-onset epilepsies.

MedPharm licenses its MedSpray ‘Patch-in-a-Can’ technology to Virpax Pharmaceuticals.

Next expansion step will increase finished product capacity for recombinant proteins by more than tenfold.

The Rocket 4D Synergy uses proprietary vacuum technology to suppress solvent bumping and foaming.

Researchers to benefit by receiving a rapid and cost-effective scaled supply of new compounds.

Acquired business will enhance Recipharm’s scale and provide access to new customers and higher margin specialised technologies.

Agreement will enable customers to achieve easier scalability of processes ranging from lab-scale to commercial-scale production of biopharmaceuticals.

The India Expo Mart brings the event closer to Indian regulatory and legislative hub and will encourage international audiences.